Henry Schein (NASDAQ:HSIC) PT Lowered to $97.00

Henry Schein (NASDAQ:HSIC – Get Rating) had its price objective decreased by equities research analysts at Credit Suisse Group from $99.00 to $97.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s price objective indicates a potential upside of 24.76% from the stock’s current price.

Several other brokerages also recently commented on HSIC. StockNews.com raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Thursday, January 19th. William Blair restated a “market perform” rating on shares of Henry Schein in a research report on Tuesday, November 1st. Morgan Stanley lowered their price objective on shares of Henry Schein from $70.00 to $69.00 and set an “underweight” rating on the stock in a research report on Tuesday, February 21st. Piper Sandler raised their price objective on shares of Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a research report on Monday, February 6th. Finally, Barrington Research lowered their price objective on shares of Henry Schein from $99.00 to $92.00 and set an “outperform” rating on the stock in a research report on Friday, February 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $85.67.

Henry Schein Stock Down 0.7 %

HSIC opened at $77.75 on Tuesday. The company has a 50 day moving average of $82.58 and a 200 day moving average of $77.07. The company has a current ratio of 1.79, a quick ratio of 0.91 and a debt-to-equity ratio of 0.25. Henry Schein has a 12 month low of $64.75 and a 12 month high of $92.68. The company has a market cap of $10.21 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 1.67 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC – Get Rating) last announced its quarterly earnings results on Thursday, February 16th. The company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.21 by $0.14. Henry Schein had a net margin of 4.25% and a return on equity of 15.79%. The firm had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.37 billion. During the same period last year, the firm earned $1.07 EPS. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. On average, sell-side analysts expect that Henry Schein will post 5.34 EPS for the current year.

Insider Buying and Selling

In related news, SVP Lorelei Mcglynn sold 15,341 shares of Henry Schein stock in a transaction on Tuesday, December 20th. The shares were sold at an average price of $80.70, for a total value of $1,238,018.70. Following the transaction, the senior vice president now owns 73,753 shares in the company, valued at approximately $5,951,867.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Henry Schein news, CEO Stanley M. Bergman sold 54,216 shares of the firm’s stock in a transaction on Monday, December 12th. The shares were sold at an average price of $81.16, for a total value of $4,400,170.56. Following the sale, the chief executive officer now owns 488,126 shares of the company’s stock, valued at approximately $39,616,306.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Lorelei Mcglynn sold 15,341 shares of the firm’s stock in a transaction on Tuesday, December 20th. The stock was sold at an average price of $80.70, for a total transaction of $1,238,018.70. Following the completion of the sale, the senior vice president now directly owns 73,753 shares in the company, valued at approximately $5,951,867.10. The disclosure for this sale can be found here. Insiders have sold a total of 76,397 shares of company stock worth $6,190,246 in the last 90 days. 1.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Henry Schein

Large investors have recently modified their holdings of the stock. UBS Group AG boosted its stake in shares of Henry Schein by 48.8% during the 3rd quarter. UBS Group AG now owns 155,032 shares of the company’s stock valued at $10,197,000 after purchasing an additional 50,840 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Henry Schein by 30.1% during the 2nd quarter. Fifth Third Bancorp now owns 1,644 shares of the company’s stock valued at $126,000 after purchasing an additional 380 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund boosted its stake in shares of Henry Schein by 15.2% during the 2nd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,717 shares of the company’s stock valued at $362,000 after purchasing an additional 624 shares in the last quarter. Hartford Investment Management Co. boosted its stake in shares of Henry Schein by 6.1% during the 3rd quarter. Hartford Investment Management Co. now owns 20,016 shares of the company’s stock valued at $1,316,000 after purchasing an additional 1,152 shares in the last quarter. Finally, Illinois Municipal Retirement Fund boosted its stake in shares of Henry Schein by 3.0% during the 2nd quarter. Illinois Municipal Retirement Fund now owns 91,125 shares of the company’s stock valued at $6,993,000 after purchasing an additional 2,693 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

About Henry Schein

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins.